(City)

(State)

(Zip)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations 1/b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Instruc	tion 1(b).			Filed							curities Exchan Company Act								
	nd Address o	of Reporting Person	*				Name ar 1 <u>y, Inc</u>				ling Symbol			i. Relationshi Check all ap Direc	plicable) ctor		,	s) to Iss	
(Last)	,	First) (I	Midd	dle)	3. Da 08/0			Trans	sactio	on (M	onth/Day/Year)	1		Offic belov	,	title er 10%	be	her (sp low) r	pecify
		STREET, SUITE	E 3 3	300	4. If A	men	idment,	Date o	of Ori	iginal	Filed (Month/D	ay/Yea		5. Individual o	or Joint/C	Group Fil	ing (Ch	eck Ar	plicable
(Street)														y Form	n filed by	One Re			
FORT W	ORTH T	X 7	610)2	Dul		OhE	1 (0)		000	action Inc	diaati	ion	Pers	OH				
(City)	(5	State) (2	Zip)		$ _{\square}$	heck	this box	to indi	icate t	that a	action Incommendation was anditions of Rule	made pu	ursuant to	a contract, ins	truction o	or written	olan tha	t is inte	nded to
		Table	l - N	Non-Deriva	<u> </u>														
1. Title of	Security (In			2. Transaction Date (Month/Day/Yea	2A. Exe	Deei cution		3. Tra	ansac ode (Ir	tion	4. Securities A Disposed Of (5)	Acquired	d (A) or	5. Amoun	t of S Ily	6. Owner Form: D (D) or Indirect (Instr. 4	irect (I)	7. Nate Indired Benef Owner (Instr.	ct ficial rship
								Co	ode	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 a	on(s)	(mour 4	,	(
Common	Stock			08/07/2023	3				S		2,900,000	D	\$41.08	6,350,	,000	I		of	anation oonses ⁽¹⁾
		Tab	ole	II - Derivati											ed	<u> </u>		(2)(3)	
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3. Transaction Date Exercise (Month/Day/Year) if a		(e.g., pu Deemed ecution Date, any onth/Day/Year)	4. Transa	Fransaction Code (Instr.		er ative rities ired	6. Date Exercisable Expiration Date (Month/Day/Year)		n Date	1		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Owner Form: Direct or Indi (I) (Ins	rship (D) irect	Beneficial Ownership (Instr. 4)	
							(Instr and 5)	Date		Expiration		Amount or Number of	1					
			<u> </u>		Code	V	(A)	(D)	Exe	rcisal	ole Date	Title	Shares						
	nd Address (P A, LL	of Reporting Person																	
(Last) C/O TPO		(First) STREET, SUITE		(Middle)															
(Street)	ORTH	TX		76102		-													
(City)		(State)		(Zip)		-													
		of Reporting Person	*																
(Last)		(First)		(Middle)															
301 CO	MMERCE	STREET, SUITE	E 33	300															
(Street)	ORTH	TX		76102															

1. Name and Address COULTER JA		
(Last)	(First)	(Middle)
C/O TPG INC.		
301 COMMERCE	E STREET, SUITE 3	3300
(Street) FORT WORTH	TX	76102
(City)	(State)	(Zip)
1. Name and Address WINKELRIEI		
		(Middle)
WINKELRIEI	<u>D JON</u>	(Middle)
(Last) C/O TPG INC.	<u>D JON</u>	, ,
(Last) C/O TPG INC.	O JON (First)	, ,
(Last) C/O TPG INC. 301 COMMERCE	O JON (First) E STREET, SUITE 3	, ,

Explanation of Responses:

- 1. Each of David Bonderman, James G. Coulter and Jon Winkelried own entities that own TPG GP A, LLC (together with Messrs. Bonderman, Coulter and Winkelried, the "Reporting Persons"), which is the managing member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., which is the managing member of TPG GPCo, LLC, which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 6,350,000 shares of Common Stock, \$0.0001 par value per share, of Progyny, Inc.
- 2. Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any.
- 3. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks:

(4) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (5) Gerald Neugebauer is signing on behalf of both Messrs. Bonderman and Coulter pursuant to authorization and designation letters dated February 26, 2020, which were previously filed with the Securities and Exchange Commission. (6) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to the authorization and designation letter dated October 12, 2020, which was previously filed with the Securities and Exchange Commission.

/s/ Bradford Berenson,
General Counsel, TPG GP A,
LLC (4).
/s/ Gerald Neugebauer, on
behalf of David Bonderman
(4)(5).
/s/ Gerald Neugebauer, on
behalf of James G. Coulter (4).
/s/ Gerald Neugebauer, on
behalf of Jon Winkelried (4).
/s/ Gerald Neugebauer, on
behalf of Jon Winkelried (4).
/s/ Gerald Neugebauer, on

** Signature of Reporting Person

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 $Note: File \ three\ copies\ of\ this\ Form,\ one\ of\ which\ must\ be\ manually\ signed.\ If\ space\ is\ insufficient,\ see\ Instruction\ 6\ for\ procedure.$

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.